Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SR 299Session 2025-2026

A Resolution designating May 14, 2026, as "IgAN Awareness Day" in Pennsylvania.

Printer's No. PN1655

See other bills
under the
same topic PRINTER'S NO. 1655 THE GENERAL ASSEMBLY OF PENNSYLVANIASENATE RESOLUTION No.299 Session of 2026 INTRODUCED BY VOGEL, STREET, TARTAGLIONE, MARTIN, HAYWOOD, PHILLIPS-HILL, CAPPELLETTI, COSTA AND HUGHES, APRIL 29, 2026 REFERRED TO RULES AND EXECUTIVE NOMINATIONS, APRIL 29, 2026 A RESOLUTIONDesignating May 14, 2026, as "IgAN Awareness Day" in Pennsylvania.WHEREAS, More than 1 in 7 American adults are estimated to have chronic kidney disease (CKD), yet as many as 9 in 10 American adults with CKD do not know they have it; andWHEREAS, While the two most common causes of kidney disease are hypertension and heart disease, the third leading cause of kidney disease is glomerulonephritis, often caused by rare, immune-mediated kidney diseases such as immunoglobulin A nephropathy (IgAN); andWHEREAS, Patients with glomerular diseases frequently advance to more costly and more debilitating later stages of kidney disease, including end-stage renal disease (ESRD), more quickly than patients with CKD in general, with estimates suggesting that rare kidney diseases make up 5% to 10% of CKD patients but account for approximately 25% of patients receiving treatment for kidney failure; andWHEREAS, Patients often face delays in being diagnosed with 123456789101112131415161718 IgAN and other immune-mediated kidney diseases, owing to the difficulty of the rare disease diagnostic odyssey, the limited number of nephrology providers and lack of awareness about the causes of kidney disease; andWHEREAS, IgAN is twice as likely to appear in men as women, can occur at any age but most likely strikes people in their 20s and 30s and is more common in Caucasians and Asians; andWHEREAS, Kidney disease, including IgAN, presents a significant burden not only on the health and lives of patients and their families, but also incurs great challenges for the health care system and health care costs of this Commonwealth, with estimates suggesting that patients with IgAN-attributed ESRD have health costs exceeding $63,000 a year; andWHEREAS, While the Federal Medicare program covers the costs of dialysis for many patients with ESRD, 45% of ESRD patients are dually eligible for Medicare and Medicaid, and ESRD is a significant source of disability, with ESRD patients employed at only one-fifth the rate of the general population; andWHEREAS, Kidney disease patients are entering a new era of hope, including for rare diseases, with multiple drugs now approved by the Food and Drug Administration to slow the progression of CKD and multiple drugs approved to slow the progression of IgAN specifically, including innovative immunology-based therapies, and more clinical trials are underway for such products; andWHEREAS, There is growing recognition that early identification of kidney disease and rare kidney diseases, including through broader screening of patients with low-cost serum creatinine blood tests and urine albuminuria creatinine ratio tests, can slow the progression of kidney disease and 20260SR0299PN1655 - 2 - 123456789101112131415161718192021222324252627282930 prevent or delay ESRD, including in patients with immune-mediated kidney diseases; andWHEREAS, "IgAN Awareness Day" is designed to increase awareness among patients, providers and policymakers of kidney disease and glomerular diseases, and IgAN in particular, to support efforts to improve policies that may increase access to screening, diagnosis and treatment for kidney disease and to provide hope and inspiration to patients, caregivers and advocates working tirelessly to advance awareness and better care for kidney disease; therefore be itRESOLVED, That the Senate designate May 14, 2026, as "IgAN Awareness Day" in Pennsylvania.20260SR0299PN1655 - 3 - 123456789101112

Official text from the Pennsylvania Legislature. Formatting has been adapted for reading on Ratifi.